2.44
price up icon2.95%   0.07
after-market After Hours: 2.45 0.01 +0.41%
loading
Editas Medicine Inc stock is traded at $2.44, with a volume of 2.26M. It is up +2.95% in the last 24 hours and down -25.84% over the past month. Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$2.37
Open:
$2.39
24h Volume:
2.26M
Relative Volume:
1.12
Market Cap:
$201.42M
Revenue:
$78.12M
Net Income/Loss:
$-153.22M
P/E Ratio:
-0.8243
EPS:
-2.96
Net Cash Flow:
$-136.90M
1W Performance:
-8.27%
1M Performance:
-25.84%
6M Performance:
-59.47%
1Y Performance:
-76.74%
1-Day Range:
Value
$2.33
$2.535
1-Week Range:
Value
$2.30
$2.69
52-Week Range:
Value
$2.30
$11.69

Editas Medicine Inc Stock (EDIT) Company Profile

Name
Name
Editas Medicine Inc
Name
Phone
617-401-9000
Name
Address
11 HURLEY ST., CAMBRIDGE, MA
Name
Employee
226
Name
Twitter
@editasmed
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
EDIT's Discussions on Twitter

Compare EDIT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
EDIT 2.44 201.42M 78.12M -153.22M -136.90M -2.96
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-08-24 Upgrade BofA Securities Neutral → Buy
May-09-24 Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-24-23 Upgrade Citigroup Neutral → Buy
Oct-18-23 Upgrade JP Morgan Underweight → Neutral
Oct-17-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-29-23 Upgrade Stifel Hold → Buy
Jun-12-23 Upgrade Raymond James Mkt Perform → Outperform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Dec-13-22 Initiated Citigroup Neutral
Dec-06-22 Resumed Credit Suisse Neutral
Nov-18-22 Downgrade Credit Suisse Outperform → Neutral
Nov-18-22 Downgrade Oppenheimer Outperform → Perform
Sep-29-22 Initiated BofA Securities Neutral
Oct-19-21 Initiated SVB Leerink Mkt Perform
Sep-24-21 Initiated Stifel Hold
Sep-10-21 Upgrade Oppenheimer Perform → Outperform
Aug-09-21 Upgrade Truist Hold → Buy
Aug-05-21 Upgrade Evercore ISI Underperform → Outperform
Jun-04-21 Resumed Robert W. Baird Outperform
May-04-21 Initiated RBC Capital Mkts Sector Perform
Apr-16-21 Initiated Goldman Sell
Mar-22-21 Initiated Credit Suisse Outperform
Mar-01-21 Downgrade Barclays Overweight → Equal Weight
Feb-26-21 Downgrade Truist Buy → Hold
Jan-19-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-07-21 Downgrade Raymond James Outperform → Mkt Perform
Dec-10-20 Upgrade Wells Fargo Equal Weight → Overweight
Nov-03-20 Initiated Robert W. Baird Underperform
Jun-18-20 Resumed SunTrust Buy
Feb-21-20 Initiated Wells Fargo Equal Weight
Apr-12-19 Initiated Evercore ISI Outperform
Oct-10-18 Initiated Guggenheim Neutral
Sep-21-18 Initiated Raymond James Outperform
May-15-18 Reiterated Chardan Capital Markets Buy
Feb-13-18 Initiated CLSA Underperform
Jan-23-18 Upgrade SunTrust Hold → Buy
Jul-14-17 Initiated SunTrust Hold
Mar-28-17 Initiated Chardan Capital Markets Buy
Aug-10-16 Upgrade Jefferies Hold → Buy
Jun-02-16 Initiated Jefferies Hold
Feb-29-16 Initiated JMP Securities Mkt Outperform
Feb-29-16 Initiated JP Morgan Neutral
Feb-29-16 Initiated Morgan Stanley Equal-Weight
View All

Editas Medicine Inc Stock (EDIT) Latest News

pulisher
Nov 22, 2024

EDIT (Editas Medicine) Price-to-Operating-Cash-Flow : (As of Nov. 22, 2024) - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Editas Medicine FY2024 EPS Forecast Lifted by Zacks Research - MarketBeat

Nov 22, 2024
pulisher
Nov 21, 2024

EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com

Nov 21, 2024
pulisher
Nov 20, 2024

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding - Simply Wall St

Nov 20, 2024
pulisher
Nov 20, 2024

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

Editas Medicine stock hits 52-week low at $2.7 amid market challenges - Investing.com India

Nov 16, 2024
pulisher
Nov 13, 2024

Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 12, 2024

Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase - Investing.com

Nov 12, 2024
pulisher
Nov 08, 2024

Cantor Fitzgerald Expects Lower Earnings for Editas Medicine - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimate for Editas Medicine Raised by Analyst - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Real Estate Capped Index (TTRE) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

S&P 500 Index (INX) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

Bristol-Myers Squibb Company (BMY-N) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 07, 2024

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve

Nov 07, 2024
pulisher
Nov 07, 2024

FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Editas Medicine upgraded at Evercore on CRISPR platform - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Editas Medicine to Present at 3 Major Healthcare Investor Conferences | EDIT Stock | EDIT Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week - Simply Wall St

Nov 06, 2024
pulisher
Nov 06, 2024

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Editas downgraded to market perform by Raymond James - MSN

Nov 06, 2024
pulisher
Nov 05, 2024

Editas Medicine (FRA:8EM) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Chardan Capital Reiterates Buy Rating for Editas Medicine (NASDAQ:EDIT) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine Buy rating and $12 target reaffirmed by Chardan - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Royal Bank of Canada Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $5.00 - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results, Hits Expectations - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine target cut to $5 by Barclays on strategic outlook - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com

Nov 05, 2024
pulisher
Nov 05, 2024

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 04, 2024

Editas Medicine Reports Q3 2024 Results and Developments - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

Editas: Q3 Earnings Snapshot - The Washington Post

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine (EDIT) PT Lowered to $5 at RBC Capital - StreetInsider.com

Nov 04, 2024
pulisher
Nov 04, 2024

Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine (NASDAQ:EDIT) Downgraded by Raymond James to "Market Perform" - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times

Nov 04, 2024

Editas Medicine Inc Stock (EDIT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):